RU2252221C2 - Производные флавонов, ксантонов и кумаринов и фармацевтическая композиция на их основе - Google Patents

Производные флавонов, ксантонов и кумаринов и фармацевтическая композиция на их основе Download PDF

Info

Publication number
RU2252221C2
RU2252221C2 RU2002108565/04A RU2002108565A RU2252221C2 RU 2252221 C2 RU2252221 C2 RU 2252221C2 RU 2002108565/04 A RU2002108565/04 A RU 2002108565/04A RU 2002108565 A RU2002108565 A RU 2002108565A RU 2252221 C2 RU2252221 C2 RU 2252221C2
Authority
RU
Russia
Prior art keywords
group
vib
alkyl
substituents
formula
Prior art date
Application number
RU2002108565/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2002108565A (ru
Inventor
Эцио БОМБАРДЕЛЛИ (IT)
Эцио БОМБАРДЕЛЛИ
Пьеро ВАЛЕНТИ (IT)
Пьеро ВАЛЕНТИ
Original Assignee
Индена С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Индена С.П.А. filed Critical Индена С.П.А.
Publication of RU2002108565A publication Critical patent/RU2002108565A/ru
Application granted granted Critical
Publication of RU2252221C2 publication Critical patent/RU2252221C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86—Oxygen atoms, e.g. xanthones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
RU2002108565/04A 1999-09-03 2000-08-28 Производные флавонов, ксантонов и кумаринов и фармацевтическая композиция на их основе RU2252221C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9920912.4 1999-09-03
GBGB9920912.4A GB9920912D0 (en) 1999-09-03 1999-09-03 Novel derivatives of flavones,xanthones and coumarins

Publications (2)

Publication Number Publication Date
RU2002108565A RU2002108565A (ru) 2003-11-10
RU2252221C2 true RU2252221C2 (ru) 2005-05-20

Family

ID=10860348

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002108565/04A RU2252221C2 (ru) 1999-09-03 2000-08-28 Производные флавонов, ксантонов и кумаринов и фармацевтическая композиция на их основе

Country Status (20)

Country Link
US (1) US6608089B2 (enExample)
EP (1) EP1212312B1 (enExample)
JP (1) JP4782337B2 (enExample)
KR (1) KR100819575B1 (enExample)
CN (1) CN1229370C (enExample)
AT (1) ATE236147T1 (enExample)
AU (1) AU775790B2 (enExample)
CA (1) CA2382129C (enExample)
CZ (1) CZ300939B6 (enExample)
DE (1) DE60001974T2 (enExample)
DK (1) DK1212312T3 (enExample)
ES (1) ES2195933T3 (enExample)
GB (1) GB9920912D0 (enExample)
HU (1) HUP0202578A3 (enExample)
NO (1) NO327911B1 (enExample)
PL (1) PL211887B1 (enExample)
PT (1) PT1212312E (enExample)
RU (1) RU2252221C2 (enExample)
SK (1) SK286402B6 (enExample)
WO (1) WO2001017985A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015424B1 (ru) * 2008-04-01 2011-08-30 Ле Лаборатуар Сервье Соединения диосметина, способ их получения и фармацевтические композиции, которые их содержат

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
PL205635B1 (pl) * 2001-04-09 2010-05-31 Inst Farmaceutyczny Nowe pochodne genisteiny i zawierające je środki farmaceutyczne
JP4664597B2 (ja) 2002-04-17 2011-04-06 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
ATE423110T1 (de) 2002-07-17 2009-03-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
EP1553911B1 (en) * 2002-08-02 2010-06-23 The Ohio State University Research Foundation 2-heterosubstituted 3-aryl-4-h-1-benzopyran-4-ones as novel therapeutics in breast cancer
WO2004024086A2 (en) * 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
KR20050095859A (ko) * 2003-02-04 2005-10-04 가부시키가이샤 야쿠루트 혼샤 유방암 내성 단백 저해제
US8404681B2 (en) 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
JP2007507539A (ja) * 2003-10-06 2007-03-29 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412768D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
CN101497593B (zh) * 2009-03-18 2011-09-21 华南理工大学 5-羟基香豆素和吡喃型香豆素类化合物及合成方法与应用
EP2560652A4 (en) * 2010-04-23 2013-08-14 Kineta Inc ANTIVIRAL CONNECTIONS
CN101985449B (zh) * 2010-09-28 2012-08-22 中山大学 一种香豆素衍生物及其制备方法和作为抗癌药物的用途
CN103113340B (zh) * 2013-01-21 2015-08-19 四川大学 一类金雀异黄酮烷基胺类化合物、其制备方法和用途
CN103232462B (zh) * 2013-05-13 2016-03-02 湖北科技学院 香豆素-吡咯类化合物的合成方法
CN103408554B (zh) * 2013-07-31 2015-07-08 西安交通大学 一种具有降高血压活性的吡咯香豆素类化合物及制备方法
CN104274455B (zh) * 2014-09-24 2018-04-27 山东理工大学 含苄基哌嗪槲皮素衍生物制法及其对胃黏膜保护作用
CN107641109B (zh) * 2017-10-16 2019-05-24 厦门大学 一种类黄酮化合物及其制备方法和应用
CN107602520B (zh) * 2017-10-16 2019-06-14 厦门大学 一种含哌嗪环的类异黄酮化合物及其制备方法和应用
KR102109151B1 (ko) 2018-06-28 2020-05-11 영남대학교 산학협력단 잔톤 유도체의 신규한 제조방법, 이로 제조된 신규한 잔톤 유도체 및 이들을 포함하는 조성물
CN110156735B (zh) * 2019-04-23 2023-05-12 天津国际生物医药联合研究院 芒柄花黄素衍生物及其制备方法和应用
CN110240579B (zh) * 2019-06-10 2023-03-31 中国科学院成都有机化学有限公司 一种多取代γ-丁内酯类化合物、制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151291A (en) * 1976-11-24 1979-04-24 Unicler Ethers of 7-hydroxy-coumarin useful as medicaments
RU2007401C1 (ru) * 1990-02-16 1994-02-15 Эли Лилли Энд Компани Способ получения трициклических соединений
RU2133745C1 (ru) * 1993-07-13 1999-07-27 Берингер Маннхайм ГмбХ Производные кумарина, их применение в качестве pla2-ингибиторов и лекарственное средство

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3513198A (en) * 1965-10-22 1970-05-19 Hoffmann La Roche Aryloxy- and arylthio-acetylenic amines and the salts thereof
JPH03163017A (ja) * 1989-08-24 1991-07-15 Nisshin Flour Milling Co Ltd 抗癌活性増強剤
US5023341A (en) 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5399561A (en) 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
JP2514500B2 (ja) * 1991-09-14 1996-07-10 呉羽化学工業株式会社 多剤耐性抑制剤及び発現阻害剤
US5663179A (en) * 1992-07-10 1997-09-02 Laboratoires Glaxo Sa Certain isoquinoline derivatives having anti-tumor properties
US5852033A (en) * 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151291A (en) * 1976-11-24 1979-04-24 Unicler Ethers of 7-hydroxy-coumarin useful as medicaments
RU2007401C1 (ru) * 1990-02-16 1994-02-15 Эли Лилли Энд Компани Способ получения трициклических соединений
RU2133745C1 (ru) * 1993-07-13 1999-07-27 Берингер Маннхайм ГмбХ Производные кумарина, их применение в качестве pla2-ингибиторов и лекарственное средство

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015424B1 (ru) * 2008-04-01 2011-08-30 Ле Лаборатуар Сервье Соединения диосметина, способ их получения и фармацевтические композиции, которые их содержат

Also Published As

Publication number Publication date
CZ300939B6 (cs) 2009-09-16
DE60001974T2 (de) 2004-02-19
US6608089B2 (en) 2003-08-19
NO20021050L (no) 2002-05-03
PT1212312E (pt) 2003-08-29
PL211887B1 (pl) 2012-07-31
KR100819575B1 (ko) 2008-04-04
SK286402B6 (sk) 2008-09-05
DE60001974D1 (de) 2003-05-08
CA2382129A1 (en) 2001-03-15
AU7000000A (en) 2001-04-10
HUP0202578A2 (hu) 2002-11-28
ES2195933T3 (es) 2003-12-16
DK1212312T3 (da) 2003-07-21
EP1212312A1 (en) 2002-06-12
HUP0202578A3 (en) 2005-02-28
NO20021050D0 (no) 2002-03-01
CZ2002785A3 (cs) 2002-06-12
NO327911B1 (no) 2009-10-19
WO2001017985A1 (en) 2001-03-15
SK3092002A3 (en) 2003-10-07
US20020183318A1 (en) 2002-12-05
JP2003508524A (ja) 2003-03-04
KR20020030801A (ko) 2002-04-25
HK1043368A1 (en) 2002-09-13
PL356699A1 (en) 2004-06-28
ATE236147T1 (de) 2003-04-15
CA2382129C (en) 2010-07-06
EP1212312B1 (en) 2003-04-02
CN1229370C (zh) 2005-11-30
JP4782337B2 (ja) 2011-09-28
CN1371371A (zh) 2002-09-25
GB9920912D0 (en) 1999-11-10
AU775790B2 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
KR100819575B1 (ko) 플라본, 잔톤 및 쿠마린의 신규 유도체
RU2266291C2 (ru) Халконовые кумарины
CN103450165B (zh) 一种2,3‑脱氢水飞蓟宾衍生物及其制备方法和用途
RU2252938C2 (ru) Халконы и фармацевтическая композиция на их основе
Fegade et al. Synthesis, molecular docking, and anticancer activity of N-heteroaryl substituted flavon derivatives
Roma et al. Pyran derivatives XX. 2-Aminochromone benzo-fused derivatives with antiproliferative properties
HK1043368B (en) Novel derivatives of flavones, xanthones and coumarins
CN104292139A (zh) 法尼基硫醚取代的查尔酮衍生物及制备方法和用途
KR100412319B1 (ko) 항암제로 유용한 3-아릴이소퀴놀린 유도체 및 그의 염
Frasinyuk et al. Synthesis of analogs of natural 2′-methoxyisoflavones
Balapure et al. Substituted phenanthrenes with basic amino side chains: A new series of anti-breast cancer agents q
Gbadebo Synthesis and Evaluation of In Vitro Cytotoxic Activities of 3-Arylcoumarins Dertivatives in Cancer Cell Lines

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130829